Clinical trials: Borderline Ovarian Tumors
Breast Cancer, Leukemia
Phase I/II Study of Escalating-Dose Melphalan w/Autologous SCS & Amifostine Cytoprotect
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Conditions
- Breast Cancer, Leukemia, Lymphoma, Neuroblastoma
- Trial name
- NCT00003425
- Testing
- filgrastim, amifostine trihydrate, cyclophosphamide
- Where
- 4 sites in United States
- Volunteers
- 25 people
- Sponsor
- University of Kentucky
Breast Cancer, Ovarian Cancer
Treating Patients With Advanced Solid Tumors, Breast Cancer or Recurrent Ovarian Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of BMS-247550 in treating patients who have metastatic…
- Conditions
- Breast Cancer, Ovarian Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- BMS-247550 (NCT00005807)
- Testing
- BMS-247550
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Albert Einstein College of Medicine
Fallopian Tube Cancer, Ovarian Cancer
Imatinib Mesylate in Treating Patients With Refractory or Relapsed Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer, or Ovarian Low Malignant Potential Tumor
RATIONALE: Imatinib mesylate may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. PURPOSE: Phase II trial to determine the effectiveness of imatinib mesylate in treating patients who have…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00039585
- Testing
- imatinib mesylate
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Cancer
Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer
RATIONALE: Suberoylanilide hydroxamic acid may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth.
- Trial name
- NCT00045006
- Testing
- vorinostat
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Ovarian Cancer
Radiolabeled Folic Acid and Imaging to Detect Ovarian Cancer
RATIONALE: Diagnostic procedures using the drug radiolabeled folic acid and imaging may be effective in detecting ovarian cancer.
- Trial name
- NCT00003763
- Testing
- radionuclide imaging, indium In 111 folic acid
- Where
- 3 sites in United States
- Volunteers
- 35 people
- Sponsor
- Endocyte
Ovarian Cancer, Borderline Ovarian Tumors
Treg, Th17 Cells, NKT in Epithelial Ovarian Tumor
The aim of the study was to estimate the percentage and of Treg, Th17 and NKT in peripheral blood and the tissue of the epithelial ovarian tumor and relationship with blood serum level of HE4, CA125, as well as algorithm ROMA.
- Conditions
- Ovarian Cancer, Borderline Ovarian Tumors, Benign Ovarian Tumor, Unexplained Infertility
- Trial name
- NCT03779399
- Testing
- Assessment of percentage of Treg, Th17, NKT and serum level of HE4, CA125 and ROMA.
- Where
- Poland
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Medical University of Lublin
Ovarian Cancer, Ovarian Tumor
AI Analysis of CT Scans to Classify Ovarian Tumours as Benign, Borderline or Malignant Before Surgery
The goal of this observational study is to learn if a computer program can tell what type of ovarian tumour a person has from a CT scan taken before surgery. The program uses artificial intelligence (AI).
- Conditions
- Ovarian Cancer, Ovarian Tumor, Borderline Ovarian Tumor
- Trial name
- OvaClass (NCT07883551)
- Where
- 7 sites in Belgium, Netherlands
- Volunteers
- 1,300 people
- Sponsor
- Catharina Ziekenhuis Eindhoven
Bladder Cancer, Breast Cancer
Chemotherapy in Treating Patients With Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of oblimersen in treating patients who have solid tumors…
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Esophageal Cancer
- Trial name
- NCT00003103
- Testing
- oblimersen sodium, docetaxel
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Ovarian Cancer, Fallopian Tube Cancer
Letrozole in Patients With Ovarian Tumors
Primary Objectives: To determine the objective response rate of Letrozole when administered to patients with advanced or recurrent borderline tumors or low-grade epithelial cancers from the ovary , fallopian tube or peritoneum.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- NCT00505661
- Testing
- Letrozole
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- M.D. Anderson Cancer Center
Low-grade Serous Ovarian Carcinoma, Recurrent Invasive Borderline Serous Ovarian Cancer
Observational Retrospective Study on Treatment and Outcomes in Patients With Low-grade Serous Ovarian Cancer
The purpose of this study is to retrospectively evaluate treatments and outcomes of patients with low grade serous ovarian carcinomas in Italy.
- Trial name
- MITO 22 (NCT02408536)
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- National Cancer Institute, Naples
Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma
Belinostat in Treating Patients With Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer or Ovarian Low Malignant Potential Tumors
This phase II trial studies how well belinostat works in treating patients with ovarian epithelial cancer, primary peritoneal cancer, or fallopian tube cancer that have spread to other places in the body or ovarian low malignant…
- Conditions
- Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma, Recurrent Borderline Ovarian Surface Epithelial-Stromal Tumor, Recurrent Ovarian Carcinoma
- Trial name
- NCT00301756
- Testing
- Belinostat, Laboratory Biomarker Analysis
- Where
- 4 sites in Canada
- Volunteers
- 32 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix
7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
This phase I trial is studying the side effects and best dose of giving 7-hydroxystaurosporine together with irinotecan hydrochloride in treating patients with metastatic or unresectable solid tumors, including triple-negative…
- Conditions
- Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix, Estrogen Receptor-negative Breast Cancer, Extensive Stage Small Cell Lung Cancer
- Trial name
- NCT00031681
- Testing
- 7-hydroxystaurosporine, irinotecan hydrochloride, diagnostic laboratory biomarker analysis
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- National Cancer Institute (NCI)
Cervical Cancer, Fallopian Tube Cancer
Gefitinib in Treating Patients With Cervical Cancer
RATIONALE: Biological therapies such as gefitinib may interfere with the growth of the tumor cells and slow the growth of cervical cancer.
- Conditions
- Cervical Cancer, Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00049556
- Testing
- gefitinib, immunohistochemistry staining method, surface-enhanced laser desorption/ionization-time of flight mass spectrometry
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Bladder Cancer, Breast Cancer
Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or…
- Conditions
- Bladder Cancer, Breast Cancer, Carcinoma of Unknown Primary, Esophageal Cancer
- Trial name
- NCT00014456
- Testing
- filgrastim, docetaxel, gemcitabine hydrochloride
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Ovarian Cancer, Ovarian Cyst Benign
Evaluation of Salivary RNAs in the Presence of an Adnexal Mass of Ovarian Origin
OVAmiARN is a multicentre, prospective, longitudinal, non-interventional, observational study carried out in 8 obstetrics and gynecology departments in France; in order to describe the evolution of salivary miRNA expression…
- Conditions
- Ovarian Cancer, Ovarian Cyst Benign, Borderline Ovarian Cancer
- Trial name
- OVAmiARN (NCT05514028)
- Testing
- Salivary samples
- Where
- 21 sites in France, Switzerland and 1 more
- Volunteers
- 746 people
- Sponsor
- ZIWIG
Ovarian Neoplasm Epithelial Borderline
Distress, Anxiety and Psychosexual Health in BOT
The aim of this study is to assess the prevalence of distress, anxiety and psychosexual anguish in patients diagnosed with borderline ovarian tumor (BOT) compared to controls confronted with surgical treatment for benign ovarian…
- Trial name
- NCT04253327
- Testing
- questionnaire
- Where
- Belgium
- Volunteers
- 60 people
- Sponsor
- Universitair Ziekenhuis Brussel
Ovarian Cancer
Squalamine Lactate Plus Carboplatin in Treating Patients With Recurrent or Refractory Stage III or Stage IV Ovarian Cancer
RATIONALE: Squalamine lactate may stop or slow the growth of ovarian cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00021385
- Testing
- carboplatin, squalamine lactate
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Adnexal Mass, Borderline Ovarian Epithelial Tumor
Folate Receptor in Diagnosing Ovarian Cancer Using Serum Samples From Patients With Newly Diagnosed Pelvic Mass or Previously Diagnosed Ovarian Cancer
This pilot research trial studies folate receptor in diagnosing ovarian cancer using serum samples from patients with a newly diagnosed pelvic mass or previously diagnosed ovarian cancer.
- Conditions
- Adnexal Mass, Borderline Ovarian Epithelial Tumor, Ovarian Clear Cell Tumor, Ovarian Endometrioid Tumor
- Trial name
- NCT02520115
- Testing
- Dexamethasone, Laboratory Biomarker Analysis, Valproic Acid
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Cervical Cancer, Endometrial Cancer
Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer
RATIONALE: Fondaparinux may help prevent blood clots from forming in patients who are undergoing surgery for gynecologic cancer.
- Conditions
- Cervical Cancer, Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer
- Trial name
- NCT00381888
- Testing
- fondaparinux sodium
- Where
- 2 sites in United States
- Volunteers
- 44 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Bladder Cancer, Breast Cancer
LMB-9 Immunotoxin in Treating Patients With Advanced Colon, Breast, Non-small Cell Lung, Bladder, Pancreatic, or Ovarian Cancer
Phase I trial to study the effectiveness of LMB-9 immunotoxin in treating patients who have advanced colon, breast, non-small cell lung, bladder, pancreatic, or ovarian cancer.
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Lung Cancer
- Trial name
- NCT00005858
- Testing
- LMB-9 immunotoxin
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- University of Maryland, Baltimore